Cargando…
PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study
BACKGROUND: Whether intensity-modulated radiotherapy (IMRT) can enhance the efficacy of the programmed death (PD)-1 inhibitors combined with anti-angiogenic therapy for hepatocellular carcinoma (HCC) is unclear. Therefore, we conducted this multicenter retrospective study to investigate the efficacy...
Autores principales: | Su, Ke, Guo, Lu, Ma, Wenqiong, Wang, Jing, Xie, Yunchuan, Rao, Mingyue, Zhang, Jianwen, Li, Xueting, Wen, Lianbin, Li, Bo, Yang, Xiaoli, Song, Yanqiong, Huang, Weihong, Chi, Hao, Gu, Tao, Xu, Ke, Liu, Yanlin, Chen, Jiali, Wu, Zhenying, Jiang, Yi, Li, Han, Zeng, Hao, Wang, Pan, Feng, Xunjie, Chen, Siyu, Yang, Binbin, Jin, Hongping, He, Kun, Han, Yunwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539675/ https://www.ncbi.nlm.nih.gov/pubmed/36211350 http://dx.doi.org/10.3389/fimmu.2022.972503 |
Ejemplares similares
-
Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study
por: Su, Ke, et al.
Publicado: (2022) -
A propensity score matching study on survival benefits of radiotherapy in patients with inoperable hepatocellular carcinoma
por: Zeng, Hao, et al.
Publicado: (2023) -
PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma
por: Su, Ke, et al.
Publicado: (2022) -
Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study
por: Su, Ke, et al.
Publicado: (2022) -
Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period
por: Su, Ke, et al.
Publicado: (2023)